



- (51) **International Patent Classification:**  
*A61K 39/395* (2006.01) *C07K 16/24* (2006.01)
- (21) **International Application Number:**  
PCT/US2013/038109
- (22) **International Filing Date:**  
25 April 2013 (25.04.2013)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
61/642,032 3 May 2012 (03.05.2012) US
- (71) **Applicant** (*for all designated States except US*):  
**BOEHRINGER INGELHEIM INTERNATIONAL GMBH** [DE/DE]; Binger Strasse 173, 55216 Ingelheim am Rhein (DE).
- (72) **Inventor; and**
- (71) **Applicant** : **NABOZNY, Gerald Henry** [US/US]; c/o VP, IP Legal, Boehringer Ingelheim USA Corp., 900 Ridgebury Rd, P.O. Box 368, Ridgefield, Connecticut 06877-0368 (US).
- (72) **Inventors:** **GALLER, Annette Bettina**; Boehringer Ingelheim GmbH, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). **GARIDEL, Patrick**; Boehringer Ingelheim GmbH, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). **LOGING, William Troy**; c/o VP, IP Legal, Boehringer Ingelheim USA Corp., 900 Ridgebury Rd, P.O. Box 368, Ridgefield, CT 06877-0368 (US). **PADULA, Steven John**; c/o VP, IP Legal, Boehringer Ingelheim USA Corp., 900 Ridgebury Rd, P.O. Box 368, Ridgefield, CT 06877-0368 (US). **SCHULTZ-FADEMRECHT, Torsten**; Boehringer Ingelheim GmbH, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). **WANG, Elaine Ee-Ling**; c/o VP, IP Legal, Boehringer Ingelheim USA Corp., 900 Ridgebury Rd, P.O. Box 368, Ridgefield, CT 06877-0368 (US).
- (74) **Agents:** **MORRIS, Michael P.** et al.; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
- *with international search report (Art. 21(3))*
  - *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
  - *with sequence listing part of description (Rule 5.2(a))*

(54) **Title:** ANTI-IL-23P19 ANTIBODIES

(57) **Abstract:** The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies, pharmaceutical compositions and therapeutic and diagnostic methods and compositions for using the same.

